D
David Baltimore
Researcher at California Institute of Technology
Publications - 882
Citations - 168784
David Baltimore is an academic researcher from California Institute of Technology. The author has contributed to research in topics: RNA & Virus. The author has an hindex of 203, co-authored 876 publications receiving 162955 citations. Previous affiliations of David Baltimore include Thomas Jefferson University & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Exploring the Limits of Ultrafast Polymerase Chain Reaction Using Liquid for Thermal Heat Exchange: A Proof of Principle
George Maltezos,Matthew L. Johnston,Konstantin Taganov,Chutatip Srichantaratsamee,John B. Gorman,David Baltimore,Wasun Chantratita,Axel Scherer +7 more
TL;DR: In a clinical setting, the system equaled or surpassed state-of-the-art devices for accuracy in amplifying DNA∕RNA of avian influenza, cytomegalovirus, and human immunodeficiency virus.
Journal ArticleDOI
Anti-VPg antibody inhibition of the poliovirus replicase reaction and production of covalent complexes of VPg-related proteins and RNA
TL;DR: Anti-VPg antibodies inhibited host-factor-dependent RNA synthesis by the poliovirus replicase but not oligo(U)-primed synthesis, implicating VPg in the de novo initiation of replic enzyme products.
Journal ArticleDOI
T-cell-specific expression of interleukin 2: evidence for a negative regulatory site.
TL;DR: To understand the basis for T-cell-specific induction of interleukin 2 (IL-2), nuclear factors from the Jurkat T-lymphoid leukemia cell are analyzed and negative regulation at this site, mediated by its associated protein(s), may contribute to the cell-specific expression of IL-2.
Journal ArticleDOI
Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules
Michael T. Bethune,Xiao-Hua Li,Jiaji Yu,Jami McLaughlin,Donghui Cheng,Colleen Mathis,Blanca Homet Moreno,Katherine Woods,Ashley Knights,Angel Garcia-Diaz,Stephanie Wong,Siwen Hu-Lieskovan,Cristina Puig-Saus,Jonathan Cebon,Jonathan Cebon,Antoni Ribas,Lili Yang,Owen N. Witte,David Baltimore +18 more
TL;DR: A general approach for expanding targeted immunotherapies to more diverse MHC haplotypes is outlined, including an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
Journal Article